Announced Thu, 2 Jul · 15:04 IST
USFDA inspection at Bengaluru facility ends with one observation
Regulatory & Legal View source PDF
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.6%1-day move
₹1659.40
prior close
₹1685.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.2+0.5—+0.6+0.2-1.6-2.9-2.1+0.8-1.2———
Up moveDown movePending
AI summary
USFDA conducted a routine cGMP inspection at OneSource Specialty Pharma's Sterile Product Division facility in Bengaluru from June 22 to June 30, 2026. The inspection concluded with one observation. The company will respond comprehensively to the FDA within the stipulated timeframe and will update stock exchanges on further developments.
Likely market impact
Single observation is generally manageable; outcome of company response and any FDA classification will determine impact on US business.